View Author
cisapride cyp 3a activity midazolam study cyp 3a infant pharmacokinetic children activity plasma concentration patient clearance adult chapter subject neonate liver disposition administration linezolid cytochrome enzyme paediatric development research difference metabolite omeprazole metabolism parameter medicine effect substrate value ratio result ontogeny figure group elimination range variability expression impact sample table pharmacology formation preterm infants drug disposition biotransformation norcisapride preterm liver microsomes study cohort plasma clearance change metoclopramide population phannacokinetic pharmacal analysis plasma concentration vs postnatal postnatal age method correlation month blood clin pharmacal function pharmacokinetic parameters disease ofmidazolam hepatic interval probe pharmacogenetic cohort
3 Most Recent Publications
|
The status of paediatric medicines initiatives around the world-what has happened and what has not?
(Article)
Hoppu, K. Anabwani, G. Garcia-Bournissen, F. Gazarian, M. Kearns, G.L. Nakamura, H. Peterson, R.G. Sri Ranganathan, S. Wildt, S.N. de |
2012-01-01
|
|
Ontogeny of midazolam glucuronidation in preterm infants
(Article)
Wildt, S.N. de Kearns, G.L. Murry, D.J. Koren, G. Anker, J.N. van den |
2010-02-01
|
|
Ontogeny and pharmacogenetics: determinants of age-associated differences in drug clearance during human development
(Doctoral Thesis)
Kearns, G.L. |
2002-10-23
|
